- Home
- UBCP vs AARD Comparison
UBCP vs AARD Comparison
Compare UBCP & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UBCP | AARD |
|---|---|---|
| Founded | 1902 | 2017 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 85.7M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | UBCP | AARD |
|---|---|---|
| Price | $16.26 | $5.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | 23.4K | ★ 139.9K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.73% | N/A |
| EPS Growth | ★ 5.51 | N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.58 | N/A |
| P/E Ratio | $12.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.47 | $3.35 |
| 52 Week High | $17.34 | $17.94 |
Technical Indicators
Market Signals| Indicator | UBCP | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 54.55 | 52.96 |
| Support Level | $14.27 | $4.74 |
| Resistance Level | $17.08 | $6.01 |
| Average True Range (ATR) | 0.45 | 0.43 |
| MACD | -0.00 | 0.17 |
| Stochastic Oscillator | 49.32 | 79.78 |
Price Performance
Historical ComparisonAbout UBCP United Bancorp Inc.
United Bancorp Inc operates as a bank holding company that provides commercial and retail banking services. Through its subsidiary (Unified Bank), the company provides a broad range of banking and financial services, which includes accepting demand, savings, and time deposits and granting commercial, real estate, and consumer loans. It serves customers in Belmont, Harrison, Jefferson, Tuscarawas, Carroll, Athens, Hocking, and Fairfield counties and the surrounding localities. The bank also operates in Marshall County West Virginia.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.